BACKGROUND: Whereas advances in minimally invasive surgery have made laparoscopic staging technically feasible in stage I epithelial ovarian cancer, the practice remains controversial because of an absence of randomized trials and lack of high-quality observational studies demonstrating equivalent outcomes. OBJECTIVE: This study seeks to evaluate the association of laparoscopic staging with survival among women with clinical stage I epithelial ovarian cancer. STUDY DESIGN: We used the National Cancer Data Base to identify all women who underwent surgical staging for clinical stage I epithelial ovarian cancer diagnosed from 2010 through 2012. The exposure of interest was planned surgical approach (laparoscopy vs laparotomy), and the primary outcome was overall survival. The primary analysis was based on an intention to treat: all women whose procedures were initiated laparoscopically were categorized as having had a planned laparoscopic procedure, regardless of subsequent conversion to laparotomy. We used propensity methods to match patients who underwent planned laparoscopic staging with similar patients who underwent planned laparotomy based on observed characteristics. We compared survival among the matched cohorts using the Kaplan-Meier method and Cox regression. We compared the extent of lymphadenectomy using the Wilcoxon rank-sum test.
O
varian cancer is the fifth leading cause of cancer-associated death among women. 1 Although most patients with epithelial ovarian cancer present with advanced-stage disease, patients with early-stage ovarian cancer have a good prognosis; the 5 year survival for patients with surgically evaluated stage I disease is approximately 90%. 2 Patients with ovarian cancer that appears confined to the ovary require surgical staging, a procedure traditionally performed via exploratory laparotomy, which includes salpingo-oophorectomy, pelvic and paraaortic lymph node dissection, omentectomy, peritoneal washings, and peritoneal biopsies. 3 Hysterectomy and removal of apparently uninvolved adnexa are also recommended for patients not seeking future fertility.
Laparoscopic surgery has been proposed as an alternative to laparotomy for surgical staging and the treatment of apparently early stage ovarian cancer. 4 Compared with laparotomy, minimally invasive surgery is associated with fewer complications and a shorter recovery period and has been adopted in earlystage endometrial cancer. 5 Although advances in minimally invasive surgery have made laparoscopic staging technically feasible in stage I epithelial ovarian cancer, the practice remains controversial because of an absence of randomized trials and lack of high-quality observational studies demonstrating equivalent outcomes.
Most published studies are small and many lack comparison groups, whereas others do not control for possible confounding. [6] [7] [8] [9] [10] [11] [12] A recent systematic review for the Cochrane Library concluded that a paucity of high-quality evidence precluded the assessment of the safety of laparoscopic staging in stage I ovarian cancer. 13 The present study uses a national tumor registry database to compare outcomes between women who underwent laparoscopic staging and those who underwent staging via laparotomy for apparent stage I epithelial ovarian cancer.
Materials and Methods
We used data from the National Cancer Data Base, a joint program of the Commission on Cancer of the American College of Surgeons and the American Cancer Society, which aggregates tumor registry data from more than 1500 hospitals and includes 70% of all incident cancer diagnosis in the United States. The National Cancer Data Base includes information about patient demographics, tumor characteristics, cancer-directed therapies (surgery, radiation, and chemotherapy), treating facility, and overall survival. This investigation was exempt from institutional review board oversight.
The study cohort flow diagram is illustrated in Figure 1 . We identified all patients diagnosed with epithelial ovarian cancer from 2010 to 2012 in the 2013 National Cancer Data Base public use data file. We defined women who underwent surgery for apparent stage I ovarian cancer as those with American Joint Committee on Cancer, seventh edition, clinical stage I, IA, IB, or IC. We also included patients with missing American Joint Committee on Cancer clinical stage who were American Joint Committee on Cancer pathological stage I, IA, IB, or IC. 15 We excluded women with cancer diagnoses that were not microscopically confirmed and those with histological codes that did not correspond to serous, mucinous, clear cell, endometrioid, or other adenocarcinoma of the ovary (Appendix Table 1) . 16 Because the National Cancer Data Base suppresses facility type for women younger than 40 years, precluding adjustment for this variable, these women were excluded. We also excluded women who did not undergo lymphadenectomy, had surgery more than 80 days after diagnosis, had missing data on surgical approach, received chemotherapy or radiation prior to surgery, or had a cancer diagnosis in addition to ovarian cancer.
The exposure of interest was a planned surgical approach. In the primary analysis, we considered all subjects whose staging procedure was initiated with a minimally invasive approach (laparoscopy or robot-assisted laparoscopy) as having undergone a planned laparoscopic staging procedure, irrespective of whether the procedure was completed laparoscopically or via laparotomy.
The primary outcome was overall survival defined as months from cancer diagnosis to death or the date of last contact as recorded by the cancer registry. Secondary outcomes included cumulative survival at 3 and 4 years after diagnosis and frequency of death within 90 days of surgery. We also compared the frequency of unplanned readmission within 30 days of surgical discharge, length of stay after surgery, and pathological lymph node count.
Control variables included patient age at the time of diagnosis (categorized as 40e49, 50e59, 60e69, 70e79, and 80 years or older), race-ethnicity (Hispanic, non-Hispanic white, non-Hispanic black, or other), tumor histology (Appendix Table 1 ), and tumor grade. Receipt of any adjuvant chemotherapy was categorized as yes, no, or unknown. We grouped tumors as smaller than 1 cm, 1.0e4.9 cm, 5.0e9.9 cm, and 10 cm or lager in tables and by 1 cm increments for the calculation of propensity scores. Extent of comorbidity was categorized as 0, 1, or more than 1 comorbidity, using the Deyo adaptation of the Charlson comorbidity index. 17, 18 The location of the treating facility was categorized by US Census region (Northeast, South, Midwest, and West). 19 We identified rural residence based on ZIP code when the US Department of Agriculture classified the county as "completely rural or less than 2500 urban population, not adjacent to a metro area." 20 The median household income, as estimated by the 2012 American Community Survey, in the subject's ZIP code of residence was used as a proxy for subjects ' 
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We compared the frequency of 30 day readmission, death within 90 days of Flow diagram of the study population and propensity-matched cohort Exclusion criteria are described on right-hand side. Utilizing an optimal algorithm to perform 1:1 propensity score matching, 1096 patients who underwent laparoscopy were successfully matched to a patient who underwent laparotomy. ajog.org GYNECOLOGY Original Research surgery, lymph node count, and postoperative length of stay using the Wilcoxon rank-sum and c 2 tests. We used propensity score matching to create a cohort in which subjects who underwent planned laparoscopy and laparotomy were balanced on measured covariates that might confound the effect of planned surgical approach on overall survival. 21 We estimated the propensity to undergo planned laparoscopic staging with a logistic regression model with variables selected a priori based on their potential to influence the likelihood of a subject undergoing laparoscopic surgery. The independent variables included age, race-ethnicity, tumor size, treating facility type, insurance status, income, number of comorbidities, census region, rural status, and year of diagnosis.
We used a 1:1 optimal matching algorithm with caliper set to 0.2 SD of the logit of the propensity score to identify matches. 22, 23 We evaluated the success of propensity score matching using absolute standardized differences, with dummy variables used in the case of nominal/ordinal covariates, considering covariates well balanced when the absolute standardized difference was less than 10% (Appendix Figure) . 24 We plotted survival functions for women who underwent planned laparoscopic staging and those who underwent planned staging laparotomy in the propensity score matched cohort using the Kaplan-Meier method and compared these using the log rank test. We estimated the hazard ratio for overall mortality after planned laparoscopic staging using a Cox proportional hazard model. We also estimated survival rates and associated 95% confidence intervals, at 3 and 4 years after diagnosis, and compared these with the Z-test for independent proportions.
To adjust for potential confounding introduced by factors that may have been evident only after surgical staging, we also calculated the hazard ratio for overall mortality after planned laparoscopic staging using a Cox proportional hazard model that included pathological stage, receipt of adjuvant chemotherapy, tumor grade, and histological type as covariates.
Sensitivity analyses
To evaluate whether the effect of planned laparoscopy was sensitive to receipt of adjuvant chemotherapy, we stratified the propensity-matched cohort by chemotherapy status and repeated the primary survival analysis in each group. To confirm that our findings persisted among patients whose procedures were planned and completed laparoscopically, we repeated all analyses after excluding women whose procedures were initiated laparoscopically but completed by laparotomy.
Because propensity score matching and Cox regression control only for observed characteristics, we investigated the robustness of the estimated treatment effect to the presence of potential unmeasured confounders. 25 We considered the possibility that 2 unobserved confounders, elevated serum CA-125, and suboptimal surgical staging were associated with both the planned surgical approach and inferior survival. We calculated the hazard ratio (with associated 95% confidence interval) for death after planned laparoscopic staging (relative to laparotomy) after adjustment for the presence of each potential confounder.
Using published data, we estimated that the preoperative CA-125 level of !30 U/mL was associated with an increased risk of death (hazard ratio, 1.65) and that undergoing suboptimal staging was associated with an increased risk of death (hazard ratio, 2.31) among patients who did not receive chemotherapy but had no effect among those who did. [25] [26] [27] We considered a range of scenarios, with the assumptions that elevated CA-125 was more prevalent among patients who underwent laparotomy and that suboptimal staging was more prevalent among subjects who underwent laparoscopy (see Appendix for details).
All statistical analysis was performed using R 3.0.3 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Of the 4798 patients who met study criteria, 1112 (23.2%) underwent planned laparoscopic surgery for clinical stage I epithelial ovarian cancer ( Figure 1 ). Of these, 190 (17.1%) had conversion to laparotomy. Among the 922 patients whose staging surgery was completed laparoscopically, 367 (39.4%) underwent robotic-assisted laparoscopy. Patients who underwent planned laparoscopic surgery were more likely to be white, receive treatment in nonacademic facilities, live in higher-income areas, reside in the Northeast or South, have private insurance, and have fewer comorbidities than patients who underwent laparotomy (Table 1 ). Laparoscopically staged patients had smaller tumors that were more frequently serous, and less frequently mucinous, than women who underwent open surgery (Table 1) .
We matched 1096 subjects (98.6%) who underwent planned laparoscopic staging to subjects who had staging by laparotomy. Associations between demographic, socioeconomic, and histopathological covariates and receipt of laparoscopic surgery, seen in the total cohort, were not evident after propensity score matching ( Table 1 ), suggesting that the matched cohort was well balanced on observed covariates. Balance of covariates was confirmed with absolute standardized differences, which were less than 10% for all variables after propensity score matching (Appendix Figure) . 14 The frequency of surgical complications as measured by death within 90 days of surgery (0.3% vs 0.9%; P ¼ .10) and unplanned readmission within 30 days of surgical discharge (2.8% vs 3.9%; P ¼ .37) did not differ between subjects who had planned laparoscopy and propensity-matched patients who had planned laparotomy (Table 2) . However, subjects who underwent planned laparoscopic surgery had higher lymph node counts (median, 14 vs 12 nodes; P ¼ .005) and shorter postoperative hospital stays (median, 3 vs 4 days; P < .001).
Women who underwent staging by laparotomy were more likely to be Original Research GYNECOLOGY ajog.org After propensity score matching, the median duration of follow-up after diagnosis was 29.9 months. There were 55 and 71 deaths in the laparoscopy and laparotomy groups, respectively. We found no significant difference in the overall survival between women who underwent planned laparoscopic staging and those who had a planned staging laparotomy (Figure 2 , rank sum P ¼.13), and time to death did not differ significantly for women who underwent staging by planned laparoscopy vs laparotomy (hazard ratio, 0.77, 95% confidence interval, 0.54e1.09).
Additionally, we found no differences in 3 and 4 year survival rates by group (Table 2) . Planned laparoscopic staging was not associated with risk of death after adjustment for receipt of adjuvant chemotherapy, histological type and grade, and pathological stage (hazard ratio, 0.82, 95% confidence interval, 0.57e1.16).
Sensitivity analyses
After stratifying the study population by receipt of adjuvant chemotherapy, we found no difference in survival between patients who underwent staging by laparoscopy and laparotomy irrespective of chemotherapy administration (not shown). In a secondary as-treated analysis, in which we excluded patients who underwent conversion from laparoscopy to laparotomy from the laparoscopic group, we found no significant difference in the overall survival between patients who underwent staging by laparoscopy and laparotomy (hazard ratio, 0.80, 95% confidence interval, 0.54e1. 19) .
In analyses assessing the sensitivity of our findings to unmeasured confounders, we found that within the range of plausible assumptions, differences in elevated preoperative serum CA-125 and suboptimal staging did not alter our conclusions about the lack of association of laparoscopic staging with survival (see Appendix). Even if CA-125 was more frequently elevated in patients who underwent laparotomy (1% vs 66%), adjustment for this confounder still did not result in a significant survival decrement for patients who underwent laparoscopy (adjusted hazard ratio, 1.16, 95% confidence interval, 0.81e1.65, Appendix Table 2 ).
When suboptimal staging in patients who did not receive adjuvant chemotherapy was assumed to be much more frequent in the planned laparoscopy group, adjustment for this potential confounder suggested a survival advantage for planned laparoscopy (Appendix Table 3 ). For example, if the prevalence of women who did not receive chemotherapy and had suboptimal staging was 20% in the laparotomy group and 40% in the laparoscopy group, adjustment for this confounder suggested that the planned laparoscopy was associated with superior survival than laparotomy (adjusted hazard ratio 0.68, 95% confidence interval, 0.74e0.96).
Comment
Minimally invasive surgery has become common in gynecological practice. Laparoscopic staging in early-stage endometrial cancer is associated with shorter recovery time, shorter hospital stay, and improved cosmetic result than staging with laparotomy. 28, 29 Nonetheless, because of a paucity of randomized trial and well-designed observational studies, there are concerns regarding the use of laparoscopy in comprehensive surgical staging of early ovarian cancer. [6] [7] [8] [9] [10] [11] [12] We have utilized a large populationbased cancer database to evaluate the effect of planned mode of surgery on overall survival among women with clinical stage I epithelial ovarian cancer. We observed no difference in survival between women who underwent planned laparoscopic staging and those who underwent staging by laparotomy. By matching on propensity to undergo planned laparoscopic staging, we were able to adjust for many variables that may confound the association between the mode of surgery and survival. Additionally, further adjustment for receipt of adjuvant chemotherapy as well as final pathological stage, grade, and histology did not influence our findings.
Our findings are consistent with previously reported retrospective series that have not demonstrated survival differences among women who underwent laparoscopic staging compared with laparotomy.
6-11 Nezhat et al 6 described a series of 20 women with ovarian and fallopian tube cancer who underwent laparoscopic staging and observed a 100% survival rate with no evidence of disease after nearly 5 years of follow-up. Tozzi et al 7 described 24 patients with stage IA or IB ovarian or fallopian tube cancer who underwent comprehensive laparoscopic staging over a 7 year period. At a median follow-up time of 46.4 months, the progression-free survival rate was 91.6%, and the overall survival rate was 100%. 7 However, 7 of the 24 patients were found to have borderline ovarian tumors, which may have skewed the follow-up data in favor of an improved survival. In a prospective study by Ghezzi et al 8 of 26 patients staged by laparoscopy, the authors reported only 1 recurrence, resulting in the death of the patient 12 months after surgery.
These results are echoed by other case series that report no recurrence or death in patients staged by laparoscopy at an [9] [10] [11] Despite the limitation of these small studies, their findings suggest that minimally invasive surgical staging of apparent early-stage epithelial ovarian cancer is safe and effective when performed by a surgeon with appropriate training. 4 Lymph node status is an important predictor of disease recurrence and survival; therefore, some authors propose that increased numbers of harvested nodes could be a marker for better surgical treatment. 30 We found that patients who underwent laparoscopy had more lymph nodes excised than those who underwent laparotomy, suggesting that staging quality was not inferior. In a study addressing feasibility of completion of laparoscopic staging for women with incompletely staged ovarian, fallopian tube, primary peritoneal, and uterine cancers sponsored by the Gynecologic Oncology Group, Spirtos et al 31 compared 58 patients who underwent comprehensive minimally invasive surgical staging with 17 patients who underwent laparotomy for completion staging, finding no difference in the number of pelvic and paraaortic lymph nodes excised.
Women from the Northeast and South underwent laparoscopic staging more frequently than those from the Midwest and West. Interestingly, patients who underwent treatment at academic centers were less likely to have laparoscopic staging than those who were treated in community settings, as were nonwhite women, women living in lower-income areas, and women without private insurance. These findings suggest that socioeconomic factors and race/ ethnicity may influence access to laparoscopic surgery for early ovarian cancer as well as clinical factors. 32, 33 Our analysis benefits from a large study population and its ability to adjust for patient's demographic characteristics, socioeconomic status, comorbidities, and adjuvant treatment. Furthermore, we found concordant results in both our primary intention to treat and secondary as-treated analyses.
Nonetheless, there are several limitations that must be considered in interpreting the findings. Surgeons' decisions regarding the surgical approach are based, at least in part, on factors that are not measured in the data, which may act as unmeasured confounders. To minimize the impact of selection bias and confounding, we used propensity score analyses, and we also tested the sensitivity of our findings to 2 potential unobserved confounders, elevated CA-125 and suboptimal staging, and our findings were robust to these analyses.
In addition, because the National Cancer Data Base began including mode of surgery in 2010, the current study has a relatively short median follow-up time, and it is possible that survival difference may emerge after further observation.
Finally, this study is underpowered to detect a small difference in survival. With 126 deaths, at a significance level of P ¼ .05, this study had 80% power to detect an unadjusted absolute difference in 4 year survival of 5.2% (91.5% vs 86.3%), similar to the absolute difference we observed in our adjusted analysis. Smaller differences may be clinically important; moreover, with a larger study population, we may have observed a small, statistically significant benefit to planned laparoscopy vs laparotomy. Furthermore, the National Cancer Data Base does not include information regarding disease recurrence, which precluded an analysis of this important outcome.
The National Cancer Data Base offers a large, nationally applicable sample to examine oncology practice patterns and outcomes in the United States. 34 Because Kaplan-Meier plot of overall survival in the propensity-matched cohort P value is based on the log rank test. 
